Mollugin prevents CLP-induced sepsis in mice by inhibiting TAK1-NF-B/ MAPKs pathways and activating Keap1-Nrf2 pathway in macrophages

Sepsis is a life-threatening organ dysfunction associated with macrophage overactivation. Targeted therapy against macrophages is considered a promising strategy for sepsis treatment. Mollugin (MLG), a compound extracted from traditional Chinese medicine Rubia cordifolia L., possesses anti-tumor and anti-inflammatory activities. This study aimed to investigate the anti-inflammatory effects and mechanisms of MLG in macro-phages and its therapeutic role in CLP-induced sepsis in mice. The results demonstrated that MLG downregulated the inflammatory response induced by LPS or tumor necrosis factor alpha (TNF-alpha) in macrophages. Mechanistically, MLG suppressed the phosphorylation of TAK1, the upstream modulator of IKK alpha/beta and MAPKs, thereby inhibiting the pro-inflammatory signaling transduction of NF-kappa B and MAPKs. Additionally, MLG also activated the Nrf2 antioxidant pathway, reducing intracellular reactive oxygen species. CETSA and molecular docking analyses revealed that MLG could effectively bind to TAK1 and Keap1, which may be involved in the inhibition of TAK1-NF-kappa B/MAPKs and activation of Nrf2 mediated by MLG. Animal study demonstrated that MLG ameliorated in-flammatory injury of lung and liver in CLP-induced sepsis mice probably by reducing the levels of pro -inflammatory cytokines. Therefore, our study suggests that bi-directional roles of MLG in improving sepsis via blocking the TAK1-NF-kappa B/MAPKs and activating Nrf2 pathways, indicating its potential as a promising candidate drug for sepsis treatment.